Briefs: Biogen Idec gets new Tecfidera patent; Fresenius Kabi to buy Indian facility

20 March 2013

US biotech firm Biogen Idec (Nasdaq: BIIB) yesterday announced that the US Patent and Trademark Office (USPTO) has granted US Patent No 8,399,514, which offers additional protection for Tecfidera (BG-12, dimethyl fumarate), the company’s much touted oral therapeutic candidate for the treatment of multiple sclerosis (MS).

The patent, which will expire in 2028, covers the dosing regimen of daily administration of 480mg of Tecfidera. Three previously obtained patents will expire between October 2019 and May 2020. This regimen is included in the proposed marketing application for Tecfidera, which is currently under review by the US Food and Drug Administration. The drug is also under review with regulators in the European Union, Australia, Canada and Switzerland.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK